Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alain Delmer

Showing results (71-80 of 109) with videos related to

Pageof 11
Sort By:
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
American Journal of Hematology|November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström MacroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
Blood|April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemiaEric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology|August 4, 2017
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)Eric Durot, Cécile Tomowiak, Anne-Sophie Michallet, et al.
American Journal of Hematology|April 5, 2019
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO groupAnne Quinquenel, Sophie Godet, Caroline Dartigeas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantationGuillaume Manson, Jean-Baptiste Mear, Charles Herbaux, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
Haematologica|February 16, 2019
Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignanciesCatherine Poirot, Anne Fortin, Nathalie Dhédin, et al.
Pageof 11

Showing results (71-80 of 109) with videos related to

Sort By:
Pageof 11
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
American Journal of Hematology|November 26, 2024
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Waldenström MacroglobulinemiaEric Durot, Lukshe Kanagaratnam, Saurabh Zanwar, et al.
Haematologica|March 10, 2018
Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) studyGuillaume Cartron, Rémi Letestu, Caroline Dartigeas, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
Blood|April 26, 2024
High efficacy of CD19 CAR T cells in patients with transformed Waldenström macroglobulinemiaEric Durot, Damien Roos-Weil, Adrien Chauchet, et al.
British Journal of Haematology|August 4, 2017
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)Eric Durot, Cécile Tomowiak, Anne-Sophie Michallet, et al.
American Journal of Hematology|April 5, 2019
Ibrutinib and idelalisib in the management of CLL-associated autoimmune cytopenias: a study from the FILO groupAnne Quinquenel, Sophie Godet, Caroline Dartigeas, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2019
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantationGuillaume Manson, Jean-Baptiste Mear, Charles Herbaux, et al.
Leukemia Research|May 25, 2023
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemiaMarie Balsat, Vincent Alcazer, Gabriel Etienne, et al.
Haematologica|February 16, 2019
Post-transplant outcome of ovarian tissue cryopreserved after chemotherapy in hematologic malignanciesCatherine Poirot, Anne Fortin, Nathalie Dhédin, et al.
Pageof 11